New Stock News | FangTuo Bio

15:39 29/08/2026

According to the Hong Kong Stock Exchange disclosure on August 28, Frontera Therapeutics (referred to as Fangtuo Biomedical) submitted a listing application to the main board of the Hong Kong Stock Exchange, with UBS Group and Haitong International as its joint sponsors.

According to a disclosure by the Hong Kong Stock Exchange on August 28, Frontera Therapeutics (abbreviated as: ) submitted a listing application to the main board of the Hong Kong Stock Exchange, with UBS Group and HAITONG INT'L as its joint sponsors. The prospectus indicates that Frontera Therapeutics is a clinical-stage gene therapy company dedicated to the independent development of recombinant adeno-associated virus (rAAV) gene therapies. The company's pipeline particularly focuses on ophthalmic and cardiovascular diseases. The company has established the rAAV gene therapy R&D platform (EXACTE) to screen candidate drugs with better tissue tropism, high transduction efficiency, long-term efficacy, and excellent safety.

Commentary on the China International Capital Corporation (CICC) Jackson Hole Meeting: The Late-arriving Hawk and the Repair of Credibility

New Stock News | Nuoling Biotechnology has submitted its application to the Hong Kong Stock Exchange again, with its products now covering 31 provinces nationwide.

New Stock News | Zhejiang Chint Electrics (601877.SH) has submitted its application to the Hong Kong Stock Exchange, maintaining its position as the leading brand in China's low voltage electrical product exports for three consecutive years.

Commentary on the China International Capital Corporation (CICC) Jackson Hole Meeting: The Late-arriving Hawk and the Repair of Credibility

New Stock News | Nuoling Biotechnology has submitted its application to the Hong Kong Stock Exchange again, with its products now covering 31 provinces nationwide.